Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 279

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 279
---
ofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 30 years in the field of sleep research, including narcolepsy and hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal has served as a Senior Medical Consultant for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debré Hospital (APHP). Dr. Konofal received his MD and PhD from University Pierre -MarieCurie in Paris, France. To approve this Proposal11, a resolution passed by a Simple Majority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 11. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 11. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 11. 122 Approval of THE Compensation for the Members of the NLS Board and Executive Management (PROPOSALs 12.1 – 12.2) Pursuant to the Swiss Code of Obligations, the shareholders’ meeting is required to vote on the remuneration that the board of directors, the executive board and the board of advisors directly or indirectly receive from the company. The Articles outline the specifics of this vote and may also stipulate the procedure to follow if the shareholders’ meeting does not approve the proposed remuneration. In accordance with the Articles, the shareholders’ meeting must approve the proposals of the board of directors in relation to: (i) the maximum aggregate amount of the compensation of the board of directors for the following term office; (ii) the maximum aggregate amount of the compensation of the executive management for the following financial year; and (iii) the maximum aggregate amount of the compensation of the members of the advisory board for the following term office. The board of directors may submit for approval by the shareholders’ meeting deviating or additional proposals relating to the same or different periods. If variable compensation is voted on prospectively, the compensation report must be submitted to the Annual General Meeting for a subsequent consultative vote. In the event the shareholders’ meeting does not approve a proposal of the board of directors regarding compensation, the board of directors is required to determine, taking into account all relevant factors, the respective